Cargando…

Remission of insomnia in older adults treated with cognitive behavioral therapy for insomnia (CBT-I) reduces p16(INK4a) gene expression in peripheral blood: secondary outcome analysis from a randomized clinical trial

Late life insomnia may increase risk for accelerated biological aging. Intervening to treat insomnia may provide protection from biological aging by reducing the prevalence of senescent cells in the immune system, as indicated by gene expression of a marker of cellular senescence, p16(INK4a). In the...

Descripción completa

Detalles Bibliográficos
Autores principales: Carroll, Judith E., Olmstead, Richard, Cole, Steve W., Breen, Elizabeth C., Arevalo, Jesusa M., Irwin, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651570/
https://www.ncbi.nlm.nih.gov/pubmed/36849678
http://dx.doi.org/10.1007/s11357-023-00741-5
_version_ 1785136026800357376
author Carroll, Judith E.
Olmstead, Richard
Cole, Steve W.
Breen, Elizabeth C.
Arevalo, Jesusa M.
Irwin, Michael R.
author_facet Carroll, Judith E.
Olmstead, Richard
Cole, Steve W.
Breen, Elizabeth C.
Arevalo, Jesusa M.
Irwin, Michael R.
author_sort Carroll, Judith E.
collection PubMed
description Late life insomnia may increase risk for accelerated biological aging. Intervening to treat insomnia may provide protection from biological aging by reducing the prevalence of senescent cells in the immune system, as indicated by gene expression of a marker of cellular senescence, p16(INK4a). In the present study, we determine whether treatment of insomnia in older adults with cognitive behavioral therapy for insomnia (CBT-I) would reduce p16(INK4a) gene expression in peripheral blood mononuclear cells (PBMC), compared to a sleep education therapy (SET), an active comparator condition. Secondly, we investigate the relationship between sustained insomnia remission and reduced expression of p16(INK4a). Participants 60 + years old with insomnia were enrolled in a randomized controlled trial and assigned to CBT-I or SET. Analyses of 231 older adults (CBT-I = 119; SET = 112) examine baseline, post (2 months), and 24 months gene expression of p16(INK4a). Compared to baseline, expression of p16(INK4a) increased in the SET group over 24 months (P = 0.03), but showed no change in the CBT-I group. Those who received CBT-I and experienced sustained remission of insomnia had a significant decline in p16(INK4a) expression by 24 months compared to baseline (P = 0.02). Individuals not sustaining remission of insomnia exhibited overall increase expression of p16(INK4a) by 24 months (P = 0.03). In older adults with insomnia, p16(INK4a) increases over 24 months, while CBT-I treatment of insomnia mitigates the increase in p16(INK4a). Further, sustained remission of insomnia using CBT-I leads to a decrease in p16(INK4a). These results suggest that behavioral interventions that are effective at treating insomnia might reduce the population of senescent cells in circulating blood. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11357-023-00741-5.
format Online
Article
Text
id pubmed-10651570
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-106515702023-02-28 Remission of insomnia in older adults treated with cognitive behavioral therapy for insomnia (CBT-I) reduces p16(INK4a) gene expression in peripheral blood: secondary outcome analysis from a randomized clinical trial Carroll, Judith E. Olmstead, Richard Cole, Steve W. Breen, Elizabeth C. Arevalo, Jesusa M. Irwin, Michael R. GeroScience Original Article Late life insomnia may increase risk for accelerated biological aging. Intervening to treat insomnia may provide protection from biological aging by reducing the prevalence of senescent cells in the immune system, as indicated by gene expression of a marker of cellular senescence, p16(INK4a). In the present study, we determine whether treatment of insomnia in older adults with cognitive behavioral therapy for insomnia (CBT-I) would reduce p16(INK4a) gene expression in peripheral blood mononuclear cells (PBMC), compared to a sleep education therapy (SET), an active comparator condition. Secondly, we investigate the relationship between sustained insomnia remission and reduced expression of p16(INK4a). Participants 60 + years old with insomnia were enrolled in a randomized controlled trial and assigned to CBT-I or SET. Analyses of 231 older adults (CBT-I = 119; SET = 112) examine baseline, post (2 months), and 24 months gene expression of p16(INK4a). Compared to baseline, expression of p16(INK4a) increased in the SET group over 24 months (P = 0.03), but showed no change in the CBT-I group. Those who received CBT-I and experienced sustained remission of insomnia had a significant decline in p16(INK4a) expression by 24 months compared to baseline (P = 0.02). Individuals not sustaining remission of insomnia exhibited overall increase expression of p16(INK4a) by 24 months (P = 0.03). In older adults with insomnia, p16(INK4a) increases over 24 months, while CBT-I treatment of insomnia mitigates the increase in p16(INK4a). Further, sustained remission of insomnia using CBT-I leads to a decrease in p16(INK4a). These results suggest that behavioral interventions that are effective at treating insomnia might reduce the population of senescent cells in circulating blood. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11357-023-00741-5. Springer International Publishing 2023-02-28 /pmc/articles/PMC10651570/ /pubmed/36849678 http://dx.doi.org/10.1007/s11357-023-00741-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Carroll, Judith E.
Olmstead, Richard
Cole, Steve W.
Breen, Elizabeth C.
Arevalo, Jesusa M.
Irwin, Michael R.
Remission of insomnia in older adults treated with cognitive behavioral therapy for insomnia (CBT-I) reduces p16(INK4a) gene expression in peripheral blood: secondary outcome analysis from a randomized clinical trial
title Remission of insomnia in older adults treated with cognitive behavioral therapy for insomnia (CBT-I) reduces p16(INK4a) gene expression in peripheral blood: secondary outcome analysis from a randomized clinical trial
title_full Remission of insomnia in older adults treated with cognitive behavioral therapy for insomnia (CBT-I) reduces p16(INK4a) gene expression in peripheral blood: secondary outcome analysis from a randomized clinical trial
title_fullStr Remission of insomnia in older adults treated with cognitive behavioral therapy for insomnia (CBT-I) reduces p16(INK4a) gene expression in peripheral blood: secondary outcome analysis from a randomized clinical trial
title_full_unstemmed Remission of insomnia in older adults treated with cognitive behavioral therapy for insomnia (CBT-I) reduces p16(INK4a) gene expression in peripheral blood: secondary outcome analysis from a randomized clinical trial
title_short Remission of insomnia in older adults treated with cognitive behavioral therapy for insomnia (CBT-I) reduces p16(INK4a) gene expression in peripheral blood: secondary outcome analysis from a randomized clinical trial
title_sort remission of insomnia in older adults treated with cognitive behavioral therapy for insomnia (cbt-i) reduces p16(ink4a) gene expression in peripheral blood: secondary outcome analysis from a randomized clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651570/
https://www.ncbi.nlm.nih.gov/pubmed/36849678
http://dx.doi.org/10.1007/s11357-023-00741-5
work_keys_str_mv AT carrolljudithe remissionofinsomniainolderadultstreatedwithcognitivebehavioraltherapyforinsomniacbtireducesp16ink4ageneexpressioninperipheralbloodsecondaryoutcomeanalysisfromarandomizedclinicaltrial
AT olmsteadrichard remissionofinsomniainolderadultstreatedwithcognitivebehavioraltherapyforinsomniacbtireducesp16ink4ageneexpressioninperipheralbloodsecondaryoutcomeanalysisfromarandomizedclinicaltrial
AT colestevew remissionofinsomniainolderadultstreatedwithcognitivebehavioraltherapyforinsomniacbtireducesp16ink4ageneexpressioninperipheralbloodsecondaryoutcomeanalysisfromarandomizedclinicaltrial
AT breenelizabethc remissionofinsomniainolderadultstreatedwithcognitivebehavioraltherapyforinsomniacbtireducesp16ink4ageneexpressioninperipheralbloodsecondaryoutcomeanalysisfromarandomizedclinicaltrial
AT arevalojesusam remissionofinsomniainolderadultstreatedwithcognitivebehavioraltherapyforinsomniacbtireducesp16ink4ageneexpressioninperipheralbloodsecondaryoutcomeanalysisfromarandomizedclinicaltrial
AT irwinmichaelr remissionofinsomniainolderadultstreatedwithcognitivebehavioraltherapyforinsomniacbtireducesp16ink4ageneexpressioninperipheralbloodsecondaryoutcomeanalysisfromarandomizedclinicaltrial